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Abstract
OBJECTIVES—To describe new users of antihypertensives and identify predictors of
combination therapy initiation among older Americans.
DESIGN—Retrospective observational cohort study.
SETTING—Population-based study using U.S. Medicare fee-for-service healthcare claims
(2007–2010).
PARTICIPANTS—275,493 Medicare beneficiaries >65 years of age with no recent diagnoses,
procedures or medications for cardiovascular disease who newly initiated antihypertensives
(210,605 initiated monotherapy and 64,888 initiated combination therapy).
MEASUREMENTS—Multivariable Poisson regression assessed factors associated with initiation
of combination versus monotherapy controlling for patient characteristics, prescriber
characteristics and patient encounters with healthcare system.
RESULTS—Initiation of combination therapy increased from 21.9% in 2007 to 24.7% in 2010.
The most frequently initiated combinations were angiotensin-converting-enzyme inhibitor/thiazide
(29.7%) and angiotensin II receptor antagonists/thiazide (18.7%). Blacks (prevalence ratio 1.48,
95% confidence interval 1.45–1.51 compared with whites), patients seeing a generalist (1.10,
1.07–1.14), patients seeing more than one doctor (3.38, 3.33–3.44), or patients with no pharmacy
claims in the last six months (1.34, 1.30–1.37 compared with three or more unique drug classes)
were more likely to initiate combination therapy, while patients who had more outpatient visits in
the last 12 months were less likely to initiate combination therapy (per five visits 0.82, 0.80–0.83).
CONCLUSION—Nearly one in four new users of antihypertensive over the age of 65 started
treatment with combination therapy. Blacks, individuals living in the South, and patients who had
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fewer outpatient physician office visits were more likely to initiate combination therapy. Further
research is needed to determine whether this approach to managing hypertension is being well-
targeted to those patients who will require combination treatment.
Keywords
Antihypertensive agents; Combination therapy; Epidemiology; Initial treatment; Medicare
beneficiaries
INTRODUCTION
The prevalence of hypertension is high in older Americans, affecting more than 65% of
people over the age of 65.1 The incidence of hypertension rises with increasing age, and
individuals who were normotensive at age 55 have an approximate 90% lifetime risk of
hypertension.2 Hypertension is an important risk factor for cardiovascular disease (CVD)
and a leading risk factor for premature death and loss of disability-adjusted life-years in the
United States.3 As the population is aging, the importance of managing hypertension in
older adults continues to increase in terms of the impact on public health.
Advances in drug therapy have made a wide variety of blood pressure lowering
antihypertensive agents available. Clinical trials have demonstrated the benefit of
antihypertensives on cardiovascular events4,5 and affirmed the benefit of treating
hypertension even in individuals over the age of 80.6,7 Most single antihypertensive agents
can reduce blood pressure by 10 to 15%, but the majority of patients ultimately require two
or more agents to achieve effective control.8
Among the many options for antihypertensive therapy, combination therapy has been
gaining more attention. Combination therapy is defined as treatment with two or more
agents administrated separately or in a fixed-dose combination pill.4,5 Initiating treatment
with combination therapy has potential benefits including improved rate of blood pressure
control and, in the case of fixed-dose combination pills, simplified treatment regimens and
better adherence.9–11 Potential disadvantages include increased cost for some combinations,
patients' perception of being sicker when prescribed more medications, risk of adverse
effects, drug burden and lower adherence rates if two pills are required.12 Given these
complex risk/benefit trade-offs, initiation of antihypertensive treatment with combination
versus monotherapy remains controversial.11–15
As the evidence and guidelines are continuously evolving, little is known about the initial
management of hypertension for older adults in the actual “real world” setting of clinical
practice. Further, patient and health care-related factors associated with initiation of
combination are not well understood. Our objectives were to describe the initial drug
management of hypertension in a large cohort of older Americans without previous
cardiovascular conditions and identify factors associated with the initiation of combination
therapy versus monotherapy.
LI et al. Page 3























Data Sources and Study Population
Using a de-identified random 20% sample of Medicare beneficiaries age 65 and older with
feefor-service Part A, B, and D coverage simultaneously in at least one calendar month
between 2007 and 2010, we identified a cohort of patients who initiated antihypertensive
therapy between July 1st, 2007 and December 31st, 2010. Eligible new users had been
continuously enrolled in Parts A and B for at least one year prior and in Part D for at least
six months. Antihypertensive drug classes in this study included angiotensin converting
enzyme inhibitors (ACEI), angiotensin II receptor antagonists (ARB), beta blockers (BB),
calcium channel blockers (CCB) and thiazide (THZ). New users of antihypertensives were
defined as patients who filled a prescription claim for any antihypertensive formulation of
interest following six antihypertensive prescription-free months. The index date was defined
as the fill date of an antihypertensive prescription. The index period ranged from the index
date through the 14th day after the index date. Eligible new users who received more than
one class of antihypertensive drug in form of fixed-dose combination pills or multiple single
drug combinations within the index period were defined as combination therapy initiators.
Patients with one unique antihypertensive drug class dispensed during the index period were
defined as monotherapy initiators. We characterized patients' demographic characteristics
and clinical conditions based on outpatient and inpatient claims occurring in the 12-month
period prior to the index date and pharmacy claims during the six months prior to the index
date.
To limit the study population to those patients who initiated antihypertensives without recent
claims for CVD related diagnoses or treatments, we excluded patients who had any code for
stroke, heart failure, myocardial infarction, angina, atrial fibrillation, revascularization or
other CVD during the 12 months preceding the index date. We further excluded patients
who had any prescription claim for warfarin, cardiac glycosides, antiplatelet drugs, nitrates
or antiarrhythmics during the six months preceding the index date. The Institutional Review
Board at the University of North Carolina at Chapel Hill approved this study.
Statistical Analyses
We categorized the new users in the final study cohort based on the index drug classes. The
prevalence ratios (PR) and 95% confidence intervals (CI) for initiating combination therapy
versus monotherapy were estimated by multivariable Poisson regression.16 Potential
predictors of combination versus monotherapy initiation included demographic
characteristics, comorbidities, procedures, number of prescribers for antihypertensives,
prescriber's specialty, number of co-medications during six months prior to the index date,
number of outpatient visits, and days of hospitalization. All analyses were conducted using
SAS version 9.3 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Between July 1st, 2007 and December 31st, 2010, we identified 275,493 Medicare
beneficiaries without recent claims for CVD initiating an antihypertensive after at least six
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antihypertensive prescription-free months. As shown in Table 1, the median age of patients
at initiation was 73 years (interquartile range 69–79). They were predominately female
(67.0%) and white (79.8%) while blacks accounted for 10.1% of the population. A large
proportion (40.4%) were from the South, 18.9% of the patients had type 2 diabetes, 55.3%
had hyperlipidemia and 4.9% were prescribed antihypertensives by a cardiologist.
Among all new antihypertensive users, 23.6% (N= 64,888) initiated combination therapy.
Compared with initiators of monotherapy, they were more likely to be black, younger and
from the South. The counties with 30% or more combination therapy initiation were
concentrated around the Southeast. Combination therapy users had fewer outpatient office
visits in the last 12 months and fewer different co-medication drug classes. Their
antihypertensives were more likely to be prescribed by a generalist.
The most commonly prescribed initial monotherapy drug class was ACEI (25.2%) followed
by THZ (15.4%) while the most frequently initiated combinations were ACEI/THZ (7.0%),
ARB/THZ (4.4%), and ACEI/CCB (2.3%). The proportion of patients being started on
combination therapy increased slightly from 21.9% in 2007 to 24.7% in 2010. The
examination of trends of initial first-line antihypertensive therapy over the study period
showed changes in the frequency of use (Appendix 1). Small increases were observed for
the use of ACEI/THZ while the use of ARB/THZ decreased slightly. Among monotherapy
options, the proportion of people initiating ACEI and CCB increased while the use of BB
and THZ decreased. The use of ARBs was relatively stable.
In multivariable analyses, we found no factors strongly associated (i.e., PR > 4.00) with
initiation of combination versus monotherapy, but several were modestly associated with
initiation of combination therapy after adjusting for other characteristics (Table 2). Among
statistically significant predictors, the strongest were race, region, prescriber specialty,
number of prescribers, outpatient physician visits and number of co-medications. Blacks
were more likely to be prescribed a combination therapy compared with whites (PR= 1.48,
95%CI: 1.45–1.51). The effect was attenuated from a crude association (PR= 1.75, 95%CI:
1.72–1.78) when race/ethnicity was the only predictor considered in the model. Patients
residing in the South, seeing more prescribers from different specialties, seeing a generalist
or those with no pharmacy claims in the last six months were also more likely to initiate
combination therapy. Patients who had any hospital stay or had more outpatient visits in the
last 12 months were less likely to initiate combination therapy, however. Having had a lipid
test or a stress test was also associated with decreased likelihood of combination therapy
initiation.
After controlling for other factors, the year of initiation of antihypertensive therapy
remained modestly predictive of combination therapy use, indicating that the observed
increase in prevalence was not fully explained by changes in the population. Patients with
type 2 diabetes or hyperlipidemia were more likely to initiate combination therapy, but
patients with a code for tobacco use or chronic obstructive pulmonary disease were less
likely to initiate combination therapy.
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In this large, national sample of older Americans without recent claims related to CVD who
began antihypertensive treatment, we found that one in four patients initiated combination
therapy. The use of combination therapy as first-line treatment increased slightly from 2007
to 2010. Nationally, counties in which at least 30% of new users received combination
therapy were concentrated in the Southeast and overlapped, to some extent, with the “stroke
belt” where higher rates of stroke and other CVD cluster.18
Among patients initiating combination therapy, the three most frequent combinations were
ACEI/THZ, ARB/THZ, and ACEI/CCB. These combinations have demonstrated synergistic
or complementary effects: ACEI/THZ,19 ARB/THZ,20 and ACEI/CCB,21 and have been
recommended as preferred choice of two-drug combinations.8 They are also available in
single-pill form, making them easier to manage and may reduce out-of-pocket patient costs.
The choice of antihypertensive therapy is normally based on blood pressure, stage of
hypertension, age, gender, race or ethnic group, coexisting conditions and the response to
previously used drugs, including the presence or absence of adverse reactions.15 In this
population of patients starting antihypertensives, with blood pressure and stage of
hypertension unobserved, we found the strongest predictors of combination therapy included
black race, number of co-medication classes and living in the South. These findings are
consistent with other research studies.14,22 Compared with whites, blacks are more likely to
have stage 2 hypertension which typically requires two or more agents to achieve blood
pressure control.4,23,24 Chronic conditions are common among older adults with more than a
third of Medicare beneficiaries having four or more chronic conditions,25 and many of these
require medication. Concerns about additional pill burden leading to difficulty with
adherence and potential drug interactions may underlie the inverse association between the
number of other medications used by the patient and the initiation of combination (rather
than mono-) therapy.
In addition to the demographic characteristics, patients' encounters with the healthcare
system were also associated with initiation of combination therapy. Compared to one
prescriber, patients seeing multiple prescribers were more than twice as likely to start on a
combination therapy. Among patients initiating combination therapy, 8.2% received
different prescriptions within 14 days from different prescribers. While the use of another
drug class in the index period might be due to adverse side effects of the initial therapy, we
think it is unlikely as most of these patients filled another prescription of the initial therapy
after adding the second drug class. It is possible that the initial therapy was not sufficient to
reach target blood pressure level and additional drug classes were deemed necessary.
Alternatively, concurrent initiation may have been inadvertent if the providers were not
aware of other interactions with the healthcare system.
Our findings should be interpreted in light of the inherent limitations of claims data. These
data do not include blood pressure levels or stage of hypertension, which should affect the
choice of first-line treatment.4,15,23 Because the indication for the prescription is not
reported on the claim, some individuals who we identified as new users of antihypertensives
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may be treated for reasons other than blood pressure control. We limited the impact of this
by excluding patients who were likely to be prescribed antihypertensives for secondary
prevention as well as new users of antihypertensive medications with known primary targets
other than blood pressure control (e.g., alpha blockers). Thirdly, the Medicare pharmacy
drug claims only capture dispensed prescriptions reimbursed by insurance. It is possible that
the cohort included patients who were not truly new initiators either because they previously
were prescribed an antihypertensive or in the event that the patient was a current user who
recently changed from paying out of pocket to using the Medicare drug benefit.26,27
However, we do not expect this to adversely impact the interpretation of our findings.
Moreover, Medicare data, as an administrative claims data, are lacking information on
alternative approaches to manage hypertension with some being used as complementary to
these pharmaceutical agents. Lastly, our findings would not generalize to other populations,
such as those with recent cardiovascular complications. Compared with Medicare
beneficiaries in general, this is a relatively healthier cohort. For instance, the average
number of comedication classes is lower than that reported in other studies of the elderly
population.28 Given that we excluded patients with any prevalent use of cardiovascular
drugs (the top prescribed therapeutic class in the elderly29), this is expected.
Our study also has several strengths. The existing literature on the “real world” practice of
antihypertensive management in the older Americans is restricted to regional12 and specific
groups of patients.22 Using the Medicare claims, the largest nationally representative data
source in the United States, we were able to examine the use of antihypertensive therapy and
provide an update of the existing literature on current clinical practice in older adults on a
large scale. Unlike data from electronic medical records, dispensed prescriptions represent
medications that patients actually received. With extensive information captured in the
claims, we were able to study new users of antihypertensives and assess the relationship
between combination therapy as initial treatment and patients' demographic, comorbidities
and co-medications, encounters with the healthcare system, and prescriber characteristics.
Some of the predictors such as comorbidities and prescriber characteristics were lacking in
the previous studies.12,22 While controlling for potential confounding with this multivariable
regression, this study identifies several important predictors of choice of initial
antihypertensive treatment among many potential factors.
In summary, nearly one in four new users of antihypertensives over age 65 started treatment
with combination therapy. Blacks were more likely to initiate combination therapy. More
research is needed to determine whether this approach to managing hypertension is being
well-targeted and results in better outcomes.
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Appendix
Appendix 1.
Trend of Initiation of Antihypertensives by Drug Class among Medicare Beneficiaries with
No Evidence of Cardiovascular Disease, United States, 2007–2010.
(ACEI = angiotensin converting enzyme inhibitors; ARB = angiotensin II receptor
antagonists; BB = beta blockers; CCB = calcium channel blockers; THZ = thiazide; Combo
= combination therapy)
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Table 1
Characteristics of New Users of Antihypertensives among Medicare Beneficiaries with No Evidence of
Cardiovascular Disease, United States, 2007–2010
Percentage, %
All N= 275,493 Monotherapy N= 210,605 Combination N= 64,888
% 100.0 76.4 23.6
Female 67.0 67.1 66.6
Race/Ethnicity 
a
White 79.8 82.0 72.9
Black 10.1 8.2 16.0
Hispanic 3.9 3.7 4.7
Other 6.2 6.1 6.4
Age 
b
Median (IQR) 73 (69–79) 73 (69–80) 73 (69–79)
66–69 28.8 28.3 30.4
70–74 27.5 27.1 28.7
75–79 18.8 18.9 18.5
80–84 13.4 13.8 12.4
85–89 7.6 7.8 6.8
90+ 3.9 4.1 3.2
Region
Midwest 23.8 24.0 23.2
Northeast 16.0 16.5 14.7
South 40.4 39.2 44.1
West 19.3 19.9 17.5
U.S. territories 0.4 0.4 0.5
Number of outpatient physician visits
in the last 12 months, median (IQR) 5 (2–8) 5 (2–9) 4 (1–7)
0 9.4 8.1 13.5
1–3 30.1 28.3 36.2
4–7 30.7 31.7 27.8
8+ 29.7 31.9 22.6
Comorbidities 
c
Chronic kidney diseases 3.3 3.4 3.2
Type 2 diabetes 18.9 18.9 18.8
Hyperlipidemia 55.3 56.2 52.5
Chronic obstructive pulmonary disease 7.4 8.0 5.7
Tobacco use 6.0 6.3 5.0
Procedures
Electrocardiography 8.1 8.4 7.0
Lipid test 44.1 45.1 41.0






















LI et al. Page 12
Percentage, %
All N= 275,493 Monotherapy N= 210,605 Combination N= 64,888
Stress test 3.9 4.2 3.1
Number of Prescribers
Median (IQR) 1 (1–1) 1 (1–1) 1 (1–1)
Prescriber Specialty 
d
Cardiologist 4.9 4.8 5.3
Other internist 34.7 34.3 35.8
Generalist 34.3 32.9 38.6
Other medical doctor
e 7.2 8.5 2.9
Nurse practitioner/Physician assistant 5.7 5.6 5.7
Other provider 0.8 0.9 0.3




0 44.3 41.6 52.7
1 27.5 28.4 24.8
2 16.0 16.9 13.2
3+ 12.2 13.1 9.3
Analgesics
Nonsteroidal anti-inflammatory drugs 12.0 12.4 10.7
Opioids 11.3 11.7 9.8
Paracetamol 9.1 9.5 7.8
Antidiabetics
Insulin 2.5 2.5 2.5
Oral antidiabetics 8.6 8.8 7.9
Mental Health
Antidementia 2.7 2.9 1.8
Antidepressants 11.8 12.7 8.6
Antiparkinson 1.7 1.9 1.1
Anxiolytics 2.3 2.4 1.8
Hypnotics 3.8 4.1 3.0
Other
Antiasthma 8.4 8.9 6.7
Hormone replacement therapy 3.9 4.3 2.9
Osteoporosis treatment 7.5 8.2 5.2
Statins 17.3 18.2 14.4
Note: All percentages are column percentages; IQR = Interquartile Range
From a cohort of 513,669 new users of antihypertensives, people initiated alpha blockers (N= 15,785), had claims for cardiovascular related
diagnoses, procedures or medications (N= 222,391) were excluded.
a
From Medicare denominator file.
b
At time of initiation.
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c
Clinical conditions were identified using definitions consisting of diagnoses with relevant International Classification of Diseases, Ninth Revision,
Clinical Medication (ICD-9-CM) codes, and procedures with Current Procedural Terminology (CPT®) codes.
d
Prescriber's specialty information was extracted from the pharmacy claims file. For patients who initiated combination therapy and had multiple
prescribers during the index period, the specially type of the second prescriber was used.
e
Other medical doctor includes physicians practicing in Emergency Medicine, Dermatology, Otolaryngology, Pain Medicine, Pathology,
Pediatrics, Psychiatry and Neurology, Surgery and etc.
f
Data regarding prescription medication fills were extracted from Part D prescription drug event files using a crosswalk between the Anatomical
Therapeutic Chemical (ATC) identifier and the National Drug Codes (NDC) adapted from First DataBank's National Drug Data File Plus.17
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Table 2
Determinants of Combination versus Monotherapy Antihypertensive Therapy Initiation among Medicare
Beneficiaries with No Evidence of Cardiovascular Disease, United States, 2007–2010
Combination versus Monotherapy




2008 1.05 1.02 1.07 1.03 1.01 1.06
2009 1.09 1.06 1.11 1.06 1.04 1.09
2010 1.12 1.10 1.15 1.08 1.06 1.11
Sex
Male 1.00 1.00




Black 1.75 1.72 1.78 1.48 1.45 1.51
Hispanic 1.30 1.26 1.34 1.21 1.17 1.26
Other 1.14 1.11 1.17 1.12 1.09 1.15
Age 
b
per 5 years older 0.96 0.95 0.96 0.96 0.95 0.96
Region
West 1.00 1.00
Midwest 1.08 1.06 1.10 1.08 1.06 1.11
Northeast 1.01 0.99 1.03 1.03 1.00 1.05
South 1.21 1.18 1.23 1.18 1.16 1.21
U.S. territories 1.30 1.19 1.42 1.25 1.11 1.40
Hospitalization in the last 12 months
None 1.00 1.00
Hospitalized in the last year 0.84 0.81 0.86 0.94 0.91 0.97
Per one more day in the hospital
c 1.00 0.99 1.00 1.00 0.99 1.00
Outpatient Visit
None 1.00 1.00
Had 1+ visit in the last 30 days 0.90 0.89 0.91 0.85 0.83 0.86
Per five visits in the last 12 months
d 0.70 0.69 0.71 0.82 0.80 0.83
Comorbidities
Chronic kidney diseases 0.96 0.92 1.00 1.00 0.96 1.04
Type 2 diabetes 1.00 0.98 1.02 1.06 1.04 1.08
Hyperlipidemia 0.89 0.88 0.90 1.06 1.04 1.08
Chronic obstructive pulmonary disease 0.75 0.73 0.77 0.92 0.89 0.95
Tobacco use 0.83 0.80 0.85 0.93 0.90 0.96
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Combination versus Monotherapy
Prevalence Ratio (95% Confidence Interval)
Unadjusted Multivariable Adjusted
Procedures
Electrocardiography 0.86 0.83 0.88 1.00 0.97 1.03
Lipid test 0.88 0.87 0.89 0.94 0.93 0.96
Stress test 0.77 0.74 0.81 0.89 0.85 0.93
Prescriber
One prescriber 1.00 1.00
Two or more prescribers 3.54 3.49 3.59 3.38 3.33 3.44
Prescriber Specialties
Cardiologist 1.00 1.00
Other internists 0.96 0.93 0.99 1.03 1.00 1.06
Other medical doctor
e 0.38 0.36 0.40 0.39 0.37 0.41
Generalist 1.05 1.02 1.09 1.10 1.07 1.14
Nurse practitioner/Physician assistant 0.94 0.90 0.98 0.98 0.94 1.02
Other provider 0.33 0.29 0.38 0.31 0.27 0.35
Number of Co-medication classes
None 1.57 1.53 1.60 1.34 1.30 1.37
One 1.18 1.15 1.21 1.11 1.08 1.14
Two 1.09 1.05 1.12 1.05 1.02 1.08
Three or more 1.00 1.00
Poisson models for unadjusted prevalence ratios and 95% confidence intervals included only the variables under consideration. Poisson models for
multivariable adjusted prevalence ratios and 95% confidence interval adjusted for all the variables listed in the table.
a
From Medicare denominator file.
b
At time of initiation, included as a linear continuous variable in the model.
c
Modeled as a continuous variable with a linear term and a quadratic term.
d
Modeled as a continuous variable with a linear term, a quadratic term and a cubic term.
e
Other medical doctor includes physicians practicing in Emergency Medicine, Dermatology, Otolaryngology, Pain Medicine, Pathology,
Pediatrics, Psychiatry and Neurology, Surgery and etc.
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